Alliance Wealth Advisors LLC UT Grows Position in Novo Nordisk A/S (NYSE:NVO)

Alliance Wealth Advisors LLC UT raised its holdings in Novo Nordisk A/S (NYSE:NVOFree Report) by 412.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,853 shares of the company’s stock after buying an additional 21,611 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Novo Nordisk A/S were worth $2,442,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in NVO. Copeland Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after purchasing an additional 141 shares in the last quarter. Bell Investment Advisors Inc boosted its position in shares of Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. Citizens National Bank Trust Department raised its stake in Novo Nordisk A/S by 100.0% during the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares during the last quarter. Centerpoint Advisors LLC purchased a new position in Novo Nordisk A/S during the third quarter valued at $28,000. Finally, Stone House Investment Management LLC raised its stake in Novo Nordisk A/S by 55.3% during the second quarter. Stone House Investment Management LLC now owns 177 shares of the company’s stock valued at $29,000 after buying an additional 63 shares during the last quarter. 6.41% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 0.9 %

Novo Nordisk A/S stock opened at $120.15 on Monday. The stock has a market cap of $539.18 billion, a PE ratio of 44.81, a price-to-earnings-growth ratio of 2.01 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. Novo Nordisk A/S has a one year low of $67.66 and a one year high of $121.65. The stock has a fifty day moving average of $105.61 and a 200 day moving average of $85.77.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Investors of record on Monday, March 25th will be given a dividend of $0.664 per share. This represents a yield of 0.9%. The ex-dividend date is Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is 22.92%.

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. TD Cowen lifted their price objective on Novo Nordisk A/S from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Monday, December 4th. Cantor Fitzgerald boosted their price target on Novo Nordisk A/S from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. UBS Group assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Monday, October 16th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $121.25.

Read Our Latest Stock Analysis on Novo Nordisk A/S

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.

Featured Articles

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.